These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Phosphorothioate-capped antisense oligonucleotides to Ras GAP inhibit cell proliferation and trigger apoptosis but fail to downregulate GAP gene expression. White JR; Gordon-Smith EC; Rutherford TR Biochem Biophys Res Commun; 1996 Oct; 227(1):118-24. PubMed ID: 8858112 [TBL] [Abstract][Full Text] [Related]
23. Locked nucleic acids: a promising molecular family for gene-function analysis and antisense drug development. Orum H; Wengel J Curr Opin Mol Ther; 2001 Jun; 3(3):239-43. PubMed ID: 11497347 [TBL] [Abstract][Full Text] [Related]
24. Antisense therapy in oncology: new hope for an old idea? Tamm I; Dörken B; Hartmann G Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935 [TBL] [Abstract][Full Text] [Related]
25. Antisense oligonucleotides as therapeutics for malignant diseases. Ho PT; Parkinson DR Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689 [TBL] [Abstract][Full Text] [Related]
27. CRE-palindrome oligonucleotide as a transcription factor decoy and an inhibitor of tumor growth. Cho-Chung YS Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):167-70. PubMed ID: 9593058 [No Abstract] [Full Text] [Related]
28. Therapeutic applications of antisense oligonucleotides in asthma and allergy. Isidoro-García M; Dávila I Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):171-5. PubMed ID: 19075979 [TBL] [Abstract][Full Text] [Related]
29. Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids. Lima WF; Crooke ST Biochemistry; 1997 Jan; 36(2):390-8. PubMed ID: 9003192 [TBL] [Abstract][Full Text] [Related]
30. Antisense oligonucleotide technology in the development of cancer therapeutics. Tseng BY; Brown KD Cancer Gene Ther; 1994 Mar; 1(1):65-71. PubMed ID: 7621240 [No Abstract] [Full Text] [Related]
31. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Kondo S; Kondo Y; Li G; Silverman RH; Cowell JK Oncogene; 1998 Jun; 16(25):3323-30. PubMed ID: 9681832 [TBL] [Abstract][Full Text] [Related]
32. TargetFinder: a software for antisense oligonucleotide target site selection based on MAST and secondary structures of target mRNA. Bo X; Wang S Bioinformatics; 2005 Apr; 21(8):1401-2. PubMed ID: 15598838 [TBL] [Abstract][Full Text] [Related]
33. Antisense oligonucleotide technology: from EST to therapeutics. Giles RV Curr Opin Mol Ther; 2000 Jun; 2(3):238-52. PubMed ID: 11249617 [TBL] [Abstract][Full Text] [Related]
34. Nuclease-resistant composite 2',5'-oligoadenylate-3', 5'-oligonucleotides for the targeted destruction of RNA: 2-5A-iso-antisense. Xiao W; Li G; Player MR; Maitra RK; Waller CF; Silverman RH; Torrence PF J Med Chem; 1998 Apr; 41(9):1531-9. PubMed ID: 9554886 [TBL] [Abstract][Full Text] [Related]
35. The design of antisense RNA. Sczakiel G Antisense Nucleic Acid Drug Dev; 1997 Aug; 7(4):439-44. PubMed ID: 9303196 [TBL] [Abstract][Full Text] [Related]
36. Development of knowledge-based therapy for cancer: identification of unique targets. Rao SG Natl Med J India; 1998; 11(6):301-2. PubMed ID: 10083808 [No Abstract] [Full Text] [Related]
37. Antisense strategies for the treatment of hematological malignancies and solid tumors. Kronenwett R; Haas R Ann Hematol; 1998; 77(1-2):1-12. PubMed ID: 9760146 [TBL] [Abstract][Full Text] [Related]